Since the inception of Alentis in 2019, we have grown to over fifty employees, started four clinical trials, and created the first two ADCs targeting Claudin-1. In this latest video our CEO Roberto Iacone and Founder Prof Thomas Baumert reveal the incredible journey from the humble beginnings till now and our bold aspirations for the future. We remain the leading biotech company developing anti-Claudin-1 therapies and are rapidly advancing our clinical pipeline to address the unmet medical needs of patients suffering from Claudin-1 positive solid tumors and organ fibrosis. Learn more at www.alentis.ch #AlentisTherapeutics #Biotech #Claudin #CLDN1
Alentis Therapeutics
Arzneimittelherstellung
Allschwil, Basel-Country 7.587 Follower:innen
We develop breakthrough treatments for Claudin1-positive tumors and organ fibrosis
Info
Alentis Therapeutics, the Claudin-1 (CLDN1) company, is a clinical stage biotechnology company on a mission to develop first-in-class antibodies and ADCs for CLDN1+ tumors and organ fibrosis. Alentis is pioneering a novel approach to modify and reverse the course of disease progression targeting CLDN1, a previously unexploited target that plays a key role in the pathology of tumors and fibrotic diseases across multiple organs. Alentis is the only company developing potential treatments for solid cancers and fibrosis targeting CLDN1. Alentis’ portfolio of anti-CLDN1 monoclonal antibodies includes a novel class of anti-cancer therapies designed to reprogram the tumor microenvironment (TME). The interplay between cancer cells and their surrounding microenvironment is highly promising for drug development as many cancers use the TME to build barriers that shield against immune system attacks. Alentis’ lead oncology asset, ALE.C04, is the first potential treatment to target CLDN1 in solid tumors. In addition, Alentis’ pipeline includes first-in-class therapies designed to modify and reverse the course of advanced organ fibrosis. ALE.F02, which is currently in Phase 1 clinical trials, is designed to target pathological overexpression of CLDN1 outside of the tight junction to resolve and reverse organ fibrosis and is being investigated for the treatment of fibrotic disease in the kidney, lung, and liver. The company was founded in 2019 based on ground-breaking research in the laboratory of Prof. Thomas Baumert MD at the University of Strasbourg and the French National Institute of Health (Inserm). Alentis is headquartered in Basel’s pharma-biotech hub in Switzerland with a subsidiary for R&D in Strasbourg, France. For more information, please visit us at www.alentis.ch or write to: info@alentis.ch
- Website
-
https://alentis.ch
Externer Link zu Alentis Therapeutics
- Branche
- Arzneimittelherstellung
- Größe
- 51–200 Beschäftigte
- Hauptsitz
- Allschwil, Basel-Country
- Art
- Privatunternehmen
- Gegründet
- 2019
- Spezialgebiete
- Claudin-1, CLDN1, Claudin, Oncology, Cancer, Kidney Fibrosis, Rare Diseases, Nephrology, Lung Fibrosis, Liver Fibrosis, ALE.C04, ALE.F02, Drug Development, Drug Discovery, Pulmonology, Hepatology, Fibrosis, Antibody-drug conjugates, ADC, HNSCC, Idiopathic pulmonary fibrosis und ANCA-associated vasculitis
Orte
-
Primär
Hegenheimermattweg 167a
Allschwil, Basel-Country 4123, CH
Beschäftigte von Alentis Therapeutics
-
Marc Adamy
Vice President -Program Management Pharmaceutical Development
-
Valentina Aureggi
SVP Business Development & Strategic Partnerships at Alentis Therapeutics
-
Michael Karl Bauer
Partner at Novo Holdings Venture Investments
-
Naveed Siddiqi
Senior Partner, Novo Holdings
Updates
-
Alentis Therapeutics hat dies direkt geteilt
Switzerland isn’t just mountains and lakes, it’s also biotech! ⛰️ Last year Swiss biotech raised over $2 billion with both public and private companies contributing. Noema Pharma and Alentis Therapeutics completed the most notable financing rounds, each securing over $100 million. 💸 With companies contributing to cancer research, gene and cell therapy, and also the biology of aging, Switzerland’s biotech ecosystem is very mature. 🧑🔬 In this article, we focus on 18 biotechs based in Switzerland! ⬇️ https://lnkd.in/d_YZ2_xz #Swissbiotech #biotechinnovation #biotechfunding #genetherapy #celltherapy #biotechecosystem #biotechstartups Araris Biotech AG | CDR-Life Inc. | CUTISS AG | Endogena Therapeutics, Inc. | Engimmune Therapeutics | FoRx Therapeutics | GlycoEra AG | HAYA Therapeutics | ImmunOs Therapeutics AG | iOnctura | MUVON Therapeutics AG | NewBiologix | Nouscom | STALICLA | Synendos Therapeutics AG | TOLREMO therapeutics | Swiss Biotech Association | Switzerland Global Enterprise | Innosuisse | Biopôle Lausanne | Basel Area Business & Innovation | BioAlps - Swiss Health Valley | Swiss Personalized Health Network (SPHN)
-
We are proud to announce that our Chief Medical Officer, Luigi Manenti, will be presenting at Venrock’s 8th Annual European Investor Tour from July 9-11 in London, UK. He will be joined by our founder, Thomas Baumert, who discovered the anti-Claudin-1 antibody, the foundation of our pipeline programs targeting cancer and fibrosis. #AlentisTherapeutics #Biotech #London
-
Team Alentis is participating in the Leerink Partners Biopharma Private Company Connect event being held virtually June 25 and 26. They´ll be highlighting our pipeline of first-in-class Claudin-1 targeting mAbs and ADCs in oncology and organ fibrosis. #AlentisTherapeutics #Biotech #Biopharma
-
The FDA has granted lixudebart (ALE.F02) Orphan Drug designation for the treatment of Idiopathic Pulmonary Fibrosis (IPF). This first-in-class monoclonal antibody is in development for liver, lung and kidney fibrosis and this designation underscores the urgent medical need for an effective IPF treatment. Read the full press release: https://lnkd.in/eNXS-TZv Prof. Steven Nathan said, “IPF patients do not have transformative treatment options and often experience tolerability challenges with the current standard of care drugs. Alentis is doing important work on developing lixudebart as a treatment targeting the root causes of disease. This molecule has shown a very favorable safety profile in Phase 1, and I would be thrilled to see lixudebart tested in IPF patients in the future.” #AlentisTherapeutics #Fibrosis #FDA #RareDisease #IPF
-
Swiss Biotech is booming! 2023 was an exceptional year, not just for Alentis but for the entire Swiss Biotech industry. Could 2024 be even better?
How has Swiss biotech been performing in 2023? 📈 In April the Swiss Biotech Report 2024 was released and its findings were very encouraging for Switzerland's biotech landscape. 2023 marked a 50% increase in capital investment compared to 2022 and reached $2.2 billion. The industry also achieved a revenue of $8 billion in Switzerland. 💸 With public and private companies raising significant funds and Swiss contributions to the cautious yet optimistic IPO market, the country remains a leader in the industry. 🏅 Find out more in the article! ⬇️ https://lnkd.in/devcxekD #swissbiotech #SwissBiotechReport #capitalinvestment #revenuegrowth #IPO #biotechindustry #innovation #healthcare #Switzerland #biotechnews #pharma NewBiologix | Noema Pharma | Alentis Therapeutics | Rejuveron Life Sciences AG | MoonLake Immunotherapeutics (NASDAQ: MLTX) | Lonza | Oculis | CRISPR Therapeutics | Vertex Pharmaceuticals | Novartis | Roche | Flatiron Health | University of Pennsylvania
-
Alentis Therapeutics hat dies direkt geteilt
Congratulations to Dr. Delbet for his great presentation "Novel therapeutic for crescentic glomerulonephritis through targeting CLDN1 in parietal epithelial cells" awarded as Top 10 Abstracts at #ERA24. Thank you Pierre-Louis Tharaux and Olivia Lenoir for this great Collaboration with Alentis Therapeutics. Proud and happy to be part of it.
-
It is International Vasculitis Day! Today we shine a light on #vasculitis and in particular ANCA-associated vasculitis (AAV). Vasculitis is used to describe a family of nearly 20 rare autoimmune diseases characterized by inflammation of the blood vessels which can damage vital organs. In the majority of AAV cases the kidneys are affected, and this often leads to significant or total loss of kidney function. At Alentis we are determined to develop lixudebart (ALE.F02) an investigational treatment to recover kidney function in AAV patients. Find out more on https://lnkd.in/gZPXSBa #VasculitisAwareness #vam2024 #ANCAVasculitis
-
Today we announced two presentations at the European Renal Association (ERA) and American Thoracic Society (ATS) conferences this May. The outstanding work performed by the research groups at @KULeuven and @Inserm show that #CLDN1 plays a key role in the early pathogenesis of #fibrosis. It further validates CLDN1 as a therapeutic target across fibrotic indications, in this case #IPF and crescentic #glomerulonephritis in ANCA-associated vasculitis. Read the full release: https://lnkd.in/ehzix_xk #AlentisTherapeutics #ERA24 #ATS2024 #Nephrology #Claudin
-
Excited to attend Bio€quity Europe! Our CEO, Roberto Iacone will give a company presentation on May 13 at 10:30 CET. Do reach out in case you want to meet up. #Bio€quity #Biotech #SeeYouThere